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Disorders of sexual development (DSD) are congenital conditions where the development of chromosomal, gonadal, or anatomic sex is atypical. Genital development 
is under the influence of sex steroids. In the steroid pathway, 
the enzyme 17 alpha-hydroxylase converts pregnenolone and 
progesterone to 17-hydroxypregnenolone and 17-hydroxy 
progesterone, respectively. This further progresses to form the 
dehydroepiandrostenidione (DHEA) under the influence of 
17, 20-lyase enzyme. 17 alpha-hydroxylase and 17, 20-lyase 
activities are catalyzed by P450c17 [1]. Sexual dimorphism and 
reproduction require 17, 20-lyase activity of P450c17 enzyme 
to synthesize androgens which subsequently get converted to 
estrogens (Fig. 1). Hence, P450c17 is an exclusive gateway to 
sex steroid production and both P450c17 and 17βHSD enzymes 
are critical in the formation of sex steroids.
P450c17 enzyme deficiency is rare and results in congenital 
adrenal hyperplasia (CAH) and accounts for ~1% cases of CAH [2]. 
This deficiency may be due to either loss of 17 alpha-hydroxylase 
activity; 17, 20-lyase; or combined activity. It is often difficult 
to distinguish these forms and a combined deficiency of both 
enzymes is often seen. Clinical spectrum varies from unambiguous 
female external genitalia to atypical genitalia, inguinal hernia, or 
palpable gonads [3,4]. These conditions usually come to notice 
during adolescence and often have hyporeninemic, hypokalemic, 
and hypertension [5].
As 11-βHSD (a form of CAH) also presents with hypertension 
and atypical genitalia, it is important to perform genetic analysis 
for a definitive diagnosis. The probability of missing diagnosis 
has been reported to be as high as 67% [6]. A biochemical pointer 
is a stimulated ratio of testosterone (T) to androstenedione (Δ4) 
of <0.8 [6]. Here, we report two cases, one with 17βHSD3 defect 
in infancy with atypical genitalia and second with CYP17A1 
which presented in childhood with novel mutations.
CASE 1
An 11-month-old reared as female, first born of a non-
consanguineous couple (full term, birth weight 2.5 kg), presented 
with complaints of atypical genitalia noticed by parents since 
5 months of age. There were no virilizing features or history of 
drug intake during antenatal period. There was no family history 
of atypical genitalia or infertility or gynecomastia noted. There was 
no history of failure to thrive, vomiting, hypoglycemia, or polyuria.
The child’s anthropometric parameters were within reference 
range [7]. There was no facial dysmorphism on examination. 
Blood pressure (BP) was 80/58 (normal). There were bilateral 
palpable gonads in the labioscrotal folds, phallus of 1 cm, slight 
rugosity, and perineoscrotal hypospadias with a single opening 
(Prader Stage 3), all suggestive of an undervirilized male 
(differential diagnosis – ovotesticular DSD, androgen synthetic 
defect, or disorders of androgen action). Systemic examination 
was unremarkable.
Ultrasound abdomen showed no Mullerian structures, both 
gonads were in labioscrotal folds and kidneys appeared to be 
normal. Karyotype was 46XY. Human chorionic gonadotropin 
(HCG) stimulation test showed basal testosterone of 0.02 ng/ml 
(Ref. – 0.75–4 ng/ml), dihydrotestosterone 29.8 pg/ml (<98 pg/ml), 
and A<0.3 ng/ml (0.1–0.3 ng/dl); 72 h after administration of HCG, 
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T was 4.48 ng/ml, dihydrotestosterone was 92.99 pg/ml, A was 
2.9 ng/ml, and T:A ratio was 2. Targeted gene sequencing detected 
a homozygous missense mutation in exon 1 of the HSD17B3 gene 
(chr9:99064268G>A; Depth: 152x) that substitutes leucine for 
proline at codon 40 (p.Pro40Leu; ENST00000375263) (Fig. 2).
A diagnosis of 46 XY 17βHSD3deficiency was made. After 
discussion with parents regarding ease of rearing a DSD child as 
a girl, the gender of rearing was decided as a female. Parents were 
counseled for gonadectomy and feminizing genitoplasty surgery.
CASE 2
A 4-year-old child being raised as a girl was referred, with sudden 
onset progressive weakness in all the 4 limbs, no history of fever, 
loose stools, vomiting, and diarrhea. She was conscious, alert, 
and afebrile with heart rate 136/min, well-felt pulses, respiratory 
rate of 20/min, spO2-100%, and BP-160/70 mmHg (Stage 2 
hypertension) [8]. Central nervous system examination revealed 
generalized hypotonia, normal deep tendon reflexes, absent 
plantar reflexes, and power of Grade 0–1 in all limbs. Other 
systems were normal.
The electrolyte estimations were suggestive of hypokalemia 
(2.3 mEq/L [3.3–4.6 mEq/L]) and hypernatremia (150 mEq/L 
[135–145 mEq/dl]), urinary osmolality was 111.4 mOsm/kg H2O 
(275–295 mOsm/kg H2O), urinary sodium (Na) was 172 mEq/L 
(normal<20 mEq/L), and potassium (K) was 52 mEq/L (in 
hypokalemia normal is <25 mEq/L). Cardiac 2D ECHO performed 
showed normal heart study. Fluids were titrated to maintain Na 
and K in reference range. BP was not controlled with nifedipine; 
hence, spironolactone was added. Ultrasonography abdomen 
Figure 2: Chromatogram showing homozygous missense mutation in exon 1 of the HSD17B3 gene (chr9:99064268G>A; Depth: 152x) that 
results in the substitution of leucine for proline at codon 40 (p.Pro40Leu; ENST00000375263) in case 1
Figure 1: Steroid biosynthetic pathway P450scc – cholesterol side-chain cleavage enzyme, 3BHSD – 3-beta-hydroxylsteroid dehydrogenase, 
P450c21 – 21-alpha-hydroxylase, P450c17 – 17-alpha-hydroxylase, and 17BDSH-III – 17-beta-hydroxylsteroid dehydrogenase 3. P450c11, 
P450c11b, and P450c11AS catalyze 11b-hydroxylase, 18-hydroxylase, and 18-methyl oxidase activities, respectively. P450aro – aromatase
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showed bilateral testes in inguinal canal (right – 9.3 mm×4.2 mm 
and left – 12 mm×5.7 mm) and no Mullerian structures.
Child’s BP was controlled and electrolytes remained 
normal. She gradually regained power and at discharge was 
ambulatory with Grade 5 power. Differential diagnosis of 11 
beta-hydroxylase steroid dehydrogenase enzyme deficiency or 
17 alpha-hydroxylase steroid dehydrogenase enzyme deficiency 
was considered. Serum cortisol was 1.33 (3–21 mcg/dl), ACTH 
was 46.2 pg/ml (6–48 pg/ml), serum aldosterone was 4.36 ng/dL 
(3–35 ng/dl), plasma renin activity was 38 ng/dl/h (50–580 ng/dl/h), 
T was 1.61 ng/dL (<0.2–3.4 ng/dL), DHEAS was19.3 mcg/dL 
(<5–57 mcg/dL), and A was <3 ng/dL (10–17 ng/dL). Karyotype 
was 46 XY, targeted exome sequencing identified homozygous 
variant (chr10:104591264C>T c.1243+1G>A) in the essential 
splice donor site in intron 7 of CYP17A1 gene.
Silico splice prediction tools (NNSPLICE and MaxEntScan) 
suggested that this variant may affect splicing due to loss of 
constitutive splice site and introduction of a new one which leads 
to frame shift and consequent premature termination of protein 
that likely results in loss of function (Fig. 3). Oral hydrocortisone 
was started; weakness and electrolytes subsequently improved. 
Spironolactone, nifedipine, and oral K supplements were tapered 
and stopped. Gonadectomy was planned and since the external 
genitals were female, steroid synthesis was impaired, and after 
parental discussion, child reared as a girl.
DISCUSSION
CYP17A1 mutations lead to disruption of steroid synthesis in 
both the adrenals and gonads. Individuals with both 46XX and 
46XY karyotype have female external genitalia as there are no 
testosterone and dihydrotestosterone in fetal life (Leydig cells 
function). Mullerian structures are not present in patients with 
46XY as the anti-Mullerian hormone is preserved (Sertoli cells 
function) [3]. Although adrenal steroid and cortisol synthesis 
are impaired in CYP17A1 defects, there is no glucocorticoid 
deficiency as corticosterone substitutes for cortisol, and thus 
adrenal crisis is rare.
Hypertension and hypokalemia are seen due to accumulation 
of deoxycortisone (DOC). Hypertension responds to 
mineralocorticoid receptor antagonists [9]. Hence, these children 
need replacement of physiological glucocorticoids, which help 
in relieving hypertension. The spectrum of clinical presentation 
in 46XY children may be atypical genitalia, inguinal hernia, 
or abdominal testes in infancy or primary amenorrhea and 
absent secondary sexual characteristics with hypertension and 
hypokalemia in adolescence [10].
CYP17A1 (located on chromosome 10q24.3) has been found 
to have 8 exons. Over 100 mutations in CYP17A1 gene have been 
associated with combined 17-hydroxylase/17, 20-lyase deficiency 
(OMIM 202110), including point mutations, small insertions or 
deletions, splice site alterations, and, rarely, large deletions [3]. 
Many of these mutations occur at C-terminus hence highlighting 
significance of the last 14 amino acids. We report a frameshift 
mutation that has not been reported previously.
Children with 17βHSD3 deficiency have female appearing 
genitalia and hence are commonly assigned female gender. 
Patients present later in childhood with inguinal hernia and 
clitoromegaly; during puberty, they present with virilization 
and amenorrhea [11,12]. In the index case 1, parents noticed a 
palpable mass and hence, DSD was suspected. There is usually 
no significant virilization in these patients, this is attributed to 
limited fetal extragonadal capacity of converting androstenedione 
(Δ4) to testosterone (T), and hence, external genitals are not 
masculinized [13].
17βHSD3 is the enzyme responsible for conversion of Δ4 to T 
and DHEA to androstenediol. When 17βHSD3 enzyme is deficient, 
higher Δ4 is found, and hence, the stimulated ratio of T/Δ4<0.8 
is said to be a diagnostic indicator of 17BHSD3 deficiency [6]. 
This ratio is also low in patients who have 46 XY dysgenic 
Figure 3: Homozygous variant (c.1243+1G>A) lies in essential splice donor site in intron 7 of CYP17A1 gene. In silico splice prediction tools 
(NNSPLICE and MaxEntScan) suggest that this variant may affect splicing due to loss of constitutive splice site
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gonads and in some cases, with partial androgen insensitivity and 
complete androgen insensitivity [6]. However, higher ratios have 
been reported in many genetically confirmed cases of 17BHSD3 
deficiency; thus, genetic testing is important [12,14]. Hence, the 
diagnosis cannot be absolutely relied on the biochemistry and 
genetic confirmation is needed. In the index case, stimulated 
T/Δ4 ratio was higher than the suggested cutoff and T:DHT ratio 
was also high; thus, genetic analysis for all 3 genes, i.e., 5-alpha 
reductase, androgen insensitivity, and 17BHSD3 were performed.
Alterations in the gene of 17βHSD3 as an etiology of DSD 
have been identified and more than 47 mutations have been 
reported [15], which include nonsense, missense, exonic deletions, 
intronic splice site duplication, and amplification mutations. The 
most common mutations in Southeast Asian populations are 
C268Y and A56T. We found a novel, hitherto unreported mutation 
in our patients with 17BHSD3 deficiency.
CONCLUSION
Defects in 17BHSD3 and CYP17A are known causes of DSD 
and have a varied presentation. A high index of suspicion is 
needed especially in children with hypertension and electrolyte 
disturbances. Genetic analysis is required to confirm the diagnosis.
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